In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus

Journal of Infectious Diseases

Volumn 180, Issue 2, 1999, Pages 262-267

  Fernández, Mario ^a,b   Quiroga, Juan Antonio ^a,b   Martín, Julio ^a,b   Herrero, Monserrat ^a,b   Pardo, Margarita ^a,b   Horisberger, Michel Andre ^c   Carreño, Vicente ^a,b  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b Fundacion para el Estudio de Las Hepatitis Virales   (Spain)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA2B INTERFERON; INTERFERON; INTERLEUKIN 2; M PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION;

2',5'-OLIGOADENYLATE SYNTHETASE; ADULT; CELLS, CULTURED; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; GTP-BINDING PROTEINS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PROTEIN BIOSYNTHESIS;

EID: 0033502248     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314859     Document Type: Article

References (33)

1. 1. Sen GC, Ransohoff RM. Interferon-induced antiviral actions and their regulation. Adv Virus Res 1993;42:57-102.
2. 2. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem 1987;56:727-77.
3. 3. Staeheli P. Interferon-induced proteins and the antiviral state. Adv Virus Res 1990;38:147-200.
4. 4. Samuel CE. Mechanisms of the antiviral action of interferons. Prog Nucleic Acid Res Mol Biol 1988;35:27-72.
5. 5. Samuel CE. Antiviral actions of interferon: interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 1991;183: 1-11.
6. 6. Pitossi F, Blank A, Schröeder A, et al. A functional GTP-binding motif is necessary for antiviral activity of Mx proteins. J Virol 1993;67:6726-32.
7. 7. Frese M, Kochs G, Feldmann H, Hertkorn C, Haller O. Inhibition of Bunyaviruses and Hantaviruses by human MxA protein. J Virol 1996;70: 915-23.
8. 8. Zhao H, De BP, Das T, Banerjee AK. Inhibition of human Parainfluenza virus-3 replication by interferon and human MxA. Virology 1996;220: 330-38.
9. 9. Meier E, Kunz G, Haller O, Arnheiter H. Activity of rat Mx proteins against a Rhabdovirus. J Virol 1990;64:6263-9.
10. 10. Pavlovic J, Zürcher T, Haller O, Staeheli P. Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein. J Virol 1990;64:3370-5.
11. 11. Ronni T, Melén K, Malygin A, Julkunen I. Control of IFN-inducible MxA gene expression in human cells. J Immunol 1993;150:1715-26.
12. 12. Towbin H, Schmitz A, Jackschies D, Von Wussow P, Horisberger MA. A whole blood immunoassay for the interferon-inducible human Mx protein. J Interferon Res 1992;12:67-74.
13. 13. Clarke B. Molecular virology of hepatitis C virus. J Gen Virol 1997;78: 2397-2410.
14. 14. Sharara AI, Hunt CM, Hamilton JD. Hepatitis C. Ann Intern Med 1996; 125:658-68.
15. 15. Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997;26(Suppl 1):71S-7S.
16. 16. Jackschies D, Zachoval R, Müller R, et al. Strong transient expression of the type I interferon-induced MxA protein in hepatitis A but not in acute hepatitis B and C. Hepatology 1994;19:857-65.
17. 17. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
18. 18. Desmet VJ, Gerber M, Hoofnagle JH, Manss M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19: 1513-20.
19. 19. Navas S, Castillo I, Martín J, Quiroga JA, Bartolomé J, Carreño V. Concordance of hepatitis C virus typing methods based on restriction fragment length polymorphism analysis in 5′ noncoding region and NS4 serotyping, but not in core PCR or a line probe assay. J Clin Microbiol 1997;35: 317-21.
20. 20. Martín J, Bosch O, Moraleda G, Bartolomé J, Quiroga JA, Carreño V. Pilot study of recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of chronic hepatitis B. Hepatology 1993;18:775-80.
21. 21. Fernández M, Quiroga JA, Martín J, Cotonat T, Pardo M, Horisberger MA, Carreño V. Impaired interferon induction of human MxA protein in chronic hepatitis B virus infection. J Med Virol 1997;51:332-7.
22. 22. Horisberger MA, Hochkeppel HK. IFN-α induced human 78 kD protein: purification and homologies with the mouse Mx protein, production of monoclonal antibodies, and potentiation effect of IFN-γ. J Interferon Res 1987;7:331-43.
23. 23. Shindo M, Okuno T, Matsumoto M, et al. Serum 2′,5′-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B. Hepatology 1988;8:366-70.
24. 24. Giannelli G, Antonelli G, Fera G, Dianzani F, Schiraldi O. 2′,5′-oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C. J Interferon Res 1993;13:57-60.
25. 25. Pawlotsky JM, Hovanessian A, Roudot-Thoraval F, et al. Activity of the interferon-induced 2′,5′-oligoadenylate synthetase in patients with chronic hepatitis C. J Interferon Cytokine Res 1995;15:857-62.
26. 26. Tsai SL, Huang SN. T cell mechanisms in the immunopathogenesis of viral hepatitis B and C. J Gastroenterol Hepatol 1997;12:S227-S35.
27. 27. Spengler U, Lechmann M, Irrgang B, Dumoulin FL, Sauerbruch T. Immune responses in hepatitis C virus infection. J Hepatol 1996;24(Suppl):20-5.
28. 28. Von Wusow P, Jackschies D, Hochkeppel HK, Fibich C, Penner L, Deicher H. The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur J Immunol 1990;20:2015-9.
29. 29. Pardo M, Castillo I, Oliva H, Fernández-Flores A, Bárcena R, de Peuter MA, Carreño V. A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C. Hepatology 1997;26:1318-21.
30. 30. Fierlbeck G, Ulmer A, Schereiner T, Stroebel W, Schiebel U, Brzoska J. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma. J Interferon Cytokine Res 1996;16:777-81.
31. 31. Karino Y, Hige S, Saga A, et al. Relationship between serum 2-5AS activity and the reduction of HCV-RNA during interferon therapy. Viral Hepatitis Liver Dis 1994;631-4.
32. 32. Chebath J, Benech P, Hovanessian A, Galabru J, Revel M. Four different forms of interferon-induced 2′,5′-oligo(A) synthetase identified by immunoblotting in human cells. J Biol Chem 1987;262:3852-7.
33. 33. Marié I, Svab J, Robert N, Galabru J, Hovanessian AG. Differential expression and distinct structure of 69-and 100-kDa forms of 2-5A synthetase in human cells treated with interferon. J Biol Chem 1990;265: 18601-7.